OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)
Stefano Piaserico, Elisabeth Riedl, Lev Pavlovsky, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 19
Stefano Piaserico, Elisabeth Riedl, Lev Pavlovsky, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 19
Showing 19 citing articles:
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 15
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 15
Psoriasis as a systemic disease
Ulrich Mrowietz, Felix Lauffer, Wiebke Sondermann, et al.
Deutsches Ärzteblatt international (2024)
Closed Access | Times Cited: 9
Ulrich Mrowietz, Felix Lauffer, Wiebke Sondermann, et al.
Deutsches Ärzteblatt international (2024)
Closed Access | Times Cited: 9
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1649-1657
Open Access | Times Cited: 4
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1649-1657
Open Access | Times Cited: 4
Emerging Contaminants: An Important But Ignored Risk Factor for Psoriasis
Lijia Huang, Ying Zhou, Hui Xiao, et al.
Clinical Reviews in Allergy & Immunology (2025) Vol. 68, Iss. 1
Closed Access
Lijia Huang, Ying Zhou, Hui Xiao, et al.
Clinical Reviews in Allergy & Immunology (2025) Vol. 68, Iss. 1
Closed Access
Management of Challenging Psoriasis Clinical Scenarios
Linda Stein Gold, Andrew Alexis, Brad Glick, et al.
Dermatology and Therapy (2025)
Open Access
Linda Stein Gold, Andrew Alexis, Brad Glick, et al.
Dermatology and Therapy (2025)
Open Access
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
Elisabeth Riedl, Andreas Pinter, Shirin Zaheri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 5, pp. 1327-1335
Open Access | Times Cited: 3
Elisabeth Riedl, Andreas Pinter, Shirin Zaheri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 5, pp. 1327-1335
Open Access | Times Cited: 3
Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023)
Yingdong Wang, Junchen Li, Chenqi Guo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Yingdong Wang, Junchen Li, Chenqi Guo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study
Zheng Zhao, Zhanglei Mu, Yan Zhao, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113474-113474
Closed Access | Times Cited: 3
Zheng Zhao, Zhanglei Mu, Yan Zhao, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113474-113474
Closed Access | Times Cited: 3
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)
Andreas Pinter, Antonio Costanzo, Sanjay Khattri, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 6, pp. 1479-1493
Open Access | Times Cited: 8
Andreas Pinter, Antonio Costanzo, Sanjay Khattri, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 6, pp. 1479-1493
Open Access | Times Cited: 8
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
Dennis McGonagle, Arthur Kavanaugh, Iain B. McInnes, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 11, pp. 3115-3123
Open Access | Times Cited: 2
Dennis McGonagle, Arthur Kavanaugh, Iain B. McInnes, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 11, pp. 3115-3123
Open Access | Times Cited: 2
Updates on Psoriasis in Special Areas
Alexandra‐Irina Butacu, Cristian Toma, Iulia-Elena Negulet, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7549-7549
Open Access | Times Cited: 2
Alexandra‐Irina Butacu, Cristian Toma, Iulia-Elena Negulet, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7549-7549
Open Access | Times Cited: 2
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
April W. Armstrong, Álvaro González‐Cantero, Saakshi Khattri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 933-952
Open Access | Times Cited: 1
April W. Armstrong, Álvaro González‐Cantero, Saakshi Khattri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 933-952
Open Access | Times Cited: 1
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study
Claudio Bonifati, Serena Lembo, Antonio Giovanni Richetta, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 1
Claudio Bonifati, Serena Lembo, Antonio Giovanni Richetta, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 1
Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
April W. Armstrong, Elisabeth Riedl, Patrick M. Brunner, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv40556-adv40556
Open Access | Times Cited: 1
April W. Armstrong, Elisabeth Riedl, Patrick M. Brunner, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv40556-adv40556
Open Access | Times Cited: 1
Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis
Sotirios G. Tsiogkas, Maria G. Grammatikopoulou, Katerina‐Maria Kontouli, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 12, pp. 1485-1498
Closed Access | Times Cited: 3
Sotirios G. Tsiogkas, Maria G. Grammatikopoulou, Katerina‐Maria Kontouli, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 12, pp. 1485-1498
Closed Access | Times Cited: 3
Characterization of psoriasis patients in special body areas: real-world evidence from the Chinese Psoriasis Standardized Diagnosis and Treatment Center
Yuge Gao, Chao Li, Meng Tong, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access
Yuge Gao, Chao Li, Meng Tong, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access
What Is New in Nail Psoriasis?
Dimitris Rigopoulos, Aikaterini Tsiogka, Dimitrios Malanos, et al.
Skin Appendage Disorders (2024), pp. 1-13
Closed Access
Dimitris Rigopoulos, Aikaterini Tsiogka, Dimitrios Malanos, et al.
Skin Appendage Disorders (2024), pp. 1-13
Closed Access
Treatment-emergent candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with Ixekizumab: an integrated safety analysis of 25 clinical studies
Sergio Schwartzman, L. Puig, Arnon D. Cohen, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Open Access
Sergio Schwartzman, L. Puig, Arnon D. Cohen, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Open Access
Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study
Xia Li, Yangfeng Ding, Chunlei Zhang, et al.
Advances in Therapy (2024)
Closed Access
Xia Li, Yangfeng Ding, Chunlei Zhang, et al.
Advances in Therapy (2024)
Closed Access
Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
Massimo Travaglini, Julia‐Tatjana Maul, Christian Kors, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2971-2983
Open Access | Times Cited: 1
Massimo Travaglini, Julia‐Tatjana Maul, Christian Kors, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2971-2983
Open Access | Times Cited: 1
